Protein S Antibodies for APC and TFPI Cofactor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for agents that can modulate the activity of Protein S, a vitamin K-dependent plasma protein involved in the anti-coagulation cascade, to address bleeding disorders and conditions characterized by reduced or impaired blood coagulation.
Innovation Solution
Development of antibodies that specifically bind to Protein S, inhibiting its cofactor activity for activated Protein C (APC) and/or tissue factor pathway inhibitor (TFPI), or promoting coagulation by modulating the coagulation cascade.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are designed to bind Protein S and inhibit its cofactor activity for APC and/or TFPI, then the ability to modulate coagulation pathways and treat bleeding disorders is improved, but the complexity of developing specific high-affinity antibodies increases
Solution Approach 1:
The patent uses phage display technology as an intermediary system to facilitate antibody development. The phage display platform serves as a mediator between the antibody gene library and the Protein S target, enabling systematic selection and identification of high-affinity binding antibodies without requiring complex direct screening methods
Solution Approach 2:
The patent performs preliminary construction of a phage display library containing antibody variants before actual screening. By pre-assembling the library with diverse antibody sequences and displaying them on phage particles, the system prepares all necessary binding candidates in advance, streamlining the subsequent selection process for Protein S-specific antibodies
2Adaptability or versatility
If existing coagulation therapies are used, then treatment options are limited, but there is a clear medical need for novel agents to address bleeding disorders
Solution Approach 1:
Instead of using traditional approaches that directly activate coagulation factors, the patent inverts the strategy by using antibodies to bind and modulate Protein S, thereby indirectly controlling coagulation pathways. This inverse approach provides novel therapeutic mechanisms that differ from conventional coagulation therapies
Solution Approach 2:
The patent alters the therapeutic parameter by targeting Protein S cofactor activity rather than directly replacing or activating coagulation factors. By changing the molecular target from coagulation factors to their regulatory protein (Protein S), the therapy achieves new mechanisms of action with potentially improved efficacy and safety profiles
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively inhibit or promote coagulation pathways, reducing bleeding disorders by enhancing clot formation and restoring thrombin generation in subjects with coagulation deficiencies.
Implementation Method 1
antibodies that bind Protein S, wherein the antibodies are inhibitors of the cofactor activity of Protein S for activated Protein C (APC), inhibitors of the cofactor activity of Protein S for tissue factor pathway inhibitor (TFPI)
Data Source
AI summary
Provided here are antibodies that bind Protein S, and methods of making and using such antibodies. In some embodiments, the Protein S antibodies provided herein are useful for treating a bleeding disorder or platelet disorder, or a condition characterized by reduced or impaired blood coagulation and/or clotting.